News from csl behring A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 08, 2015, 10:00 ET

Centers for Medicare and Medicaid Services Extends New Technology Add-On Payment for CSL Behring's Kcentra® for Third Year

 CSL Behring today announced that the Centers for Medicare and Medicaid Services (CMS) again extended the new technology add-on payment...

Aug 25, 2015, 09:01 ET
CSL Behring logo

CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors

 CSL Behring announced today that the first patient has been enrolled in its Phase II/III clinical study evaluating the pharmacokinetics (PK),...

Jul 28, 2015, 09:01 ET

Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B

 CSL Behring announced today that Swissmedic has accepted for review a Marketing Authorization Application (MAA) for the company's...

Jul 28, 2015, 09:00 ET

U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A

CSL Behring announced today that the U.S. Food and Drug Administration has accepted for review the company's Biologics License Application (BLA)...

Jun 29, 2015, 13:30 ET

CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient

 CSL Behring announced today that Mohammad Alsharabati, MD, University of Alabama at Birmingham, United States, is the recipient of the 2015...

Jun 24, 2015, 17:16 ET
CSL Behring logo.

CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015

- Data supports prolonged dosing intervals up to 14 days for routine prophylaxis in hemophilia B patients - Majority of adult and pediatric...

Jun 24, 2015, 08:31 ET
CSL Behring logo.

CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A

Data Presented during Late Breaking Session at the 2015 ISTH Congress showed: - Patients using rVIII-SingleChain prophylactically to prevent...

Jun 17, 2015, 12:15 ET
CSL Behring logo.

Defining And Differentiating The Value Of Therapies Used To Treat Rare Disease Patients Is A Challenge For Payers

 The cost of medicines in general and biopharmaceutical therapies used to treat rare diseases in particular has faced increased attention from...

Jun 16, 2015, 09:00 ET
CSL Behring logo.

CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at 2015 ISTH Congress

More than 20 abstracts focusing on investigational and branded products showcase CSL Behring's expertise and commitment to advancing the care of...

Jun 01, 2015, 09:00 ET

Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1 Antitrypsin Deficiency (AATD)

Findings from CSL Behring's RAPID study, the largest placebo-controlled trial ever conducted in patients with alpha-1 antitrypsin deficiency...

May 22, 2015, 09:00 ET

National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award

 The National Hemophilia Foundation (NHF) has awarded CSL Behring its 2015 Corporate Leadership Award as recognition for the company's...

May 14, 2015, 09:00 ET
CSL Behring logo

Science, Information, And Technology Driving Evolution Of Global Healthcare

 Scientific advancements, more readily available medical information and emerging technologies are driving greater patient engagement,...

Apr 23, 2015, 09:07 ET
CSL Behring logo

CSL Behring Awards Young Researchers Around the World to Advance Coagulation Science

CSL Behring Professor Heimburger Award Provides 100,000 Euros in Start-Up Grants to Emerging Coagulation Investigators; Underscores CSL...

Apr 14, 2015, 09:30 ET
World Federation of Hemophilia Logo

CSL Behring Marks World Hemophilia Day by Renewing Pledge to World Federation of Hemophilia

CSL Behring to Donate 10 Million IUs of its Bleeding Disorder Protein Therapies and to Contribute More than $1.1 Million in Financial Support to...

Mar 30, 2015, 08:58 ET
CSL Behring logo.

European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients

rIX-FP Regulatory Submissions Now Made in EU and U.S.; Underscores CSL Behring's Legacy of Improving the Care for Patients with Bleeding...

Mar 17, 2015, 09:00 ET

The Lancet Publishes CSL Behring's Kcentra® Phase III Data

CSL Behring today announced that The Lancet has published results from a Phase III clinical study showing Kcentra® (Prothrombin Complex...

Mar 09, 2015, 09:00 ET
CSL Behring employees take time out from their work day to package clothes, shoes, books, toys, baby safety equipment and school supplies for thousands of children in the Philadelphia area as part of the Cradles to Crayons program. Cradles to Crayons is one of many charitable programs supported by CSL Behring and its employees throughout the year.

CSL Behring to Provide $80,000 in Scholarship Funding For Low-Income Students in Philadelphia Area

CSL Behring announced that it is partnering with Children's Scholarship Fund Philadelphia (CSFP) to support scholarships for low-income students....

Feb 27, 2015, 09:00 ET
CSL Behring logo

CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia

 In recognition of Rare Disease Day and as part of its ongoing commitment to the global bleeding disorders community, CSL Behring announced...

Feb 04, 2015, 11:00 ET
CSL Behring logo

U.S. FDA Accepts for Review CSL Behring's Biologics License Application for rIX-FP for Hemophilia B Patients

CSL Behring Achieves Another Key Milestone in PROLONG-9FP, its Recombinant Factor IX Fusion Protein Development Program; Continues to Advance CSL...

Feb 02, 2015, 09:00 ET

FDA Approves New Dosing Option for CSL Behring's Hizentra®

 CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has expanded the administration options...